Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients

A hard-charging group of Novartis execs have been pouring over the late-stage data they gathered to support their successful campaign to win an FDA approval for Mayzent (siponimod) as a landmark new therapy for multiple sclerosis. And it’s paid off.